الصحافة

مقالات النشر

عناوين عن الشركات التي نرتبها، المجمعة من مصادر الأخبار العامة. نحن نربط بالمقالة الأصلية ولا نعيد نشرها — علامات المشاعر قائمة على الكلمات المفتاحية، وليس الحكم التحريري.

عرض التغطية الخاصة ب Teva Pharmaceutical

27 عناوين · 1,721 شركة مغطاة

من 1 إلى 27 من 27

2026-10-20
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease - Koreabizwire
Teva Pharmaceutical· koreabizwire.com
2026-10-18
Teva Pharmaceutical Industries (TEVA) Gets FDA Nod For Monthly Schizophrenia Injection - Simply Wall Street
Teva Pharmaceutical· simplywall.st
2026-10-15
Teva Pharmaceutical Industries (NYSE:TEVA) Given New $47.00 Price Target at Barclays - MarketBeat
Teva Pharmaceutical· www.marketbeat.com
2026-10-15
Israel Elections: AI Stocks, A Defense Winner And Oil Prices In Focus
Teva Pharmaceutical· finance.yahoo.com
2026-10-15
Cash per share of Teva Pharmaceutical Industries Limited – BIVA:TEVA1/N - TradingView
Teva Pharmaceutical· www.tradingview.com
2026-10-13
Nvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value Gems
Teva Pharmaceutical· finance.yahoo.com
2026-10-13
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
Teva Pharmaceutical· finance.yahoo.com
2026-10-13
MedinCell (ENXTPA:MEDCL) Stock Could Be Overvalued On FDA Approval News
Teva Pharmaceutical· finance.yahoo.com
2026-10-12
Teva to Host R&D Day on Wednesday, November 11 in New York City
Teva Pharmaceutical· finance.yahoo.com
2026-10-12
TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament
Teva Pharmaceutical· barchart.com
2026-10-12
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva Pharmaceutical· finance.yahoo.com
2026-10-12
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs
Teva Pharmaceutical· finance.yahoo.com
2026-10-12
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
Teva Pharmaceutical· finance.yahoo.com
2026-10-12
FDA approves Teva’s monthly injection of olanzapine for schizophrenia
Teva Pharmaceutical· pharmaceutical-technology.com
2026-10-12
Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters
Teva Pharmaceutical· www.reuters.com
2026-10-09
Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot
Teva Pharmaceutical· stocktwits.com
2026-10-09
Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva Pharmaceutical· marketbeat.com
2026-10-09
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
Teva climbs premarket as FDA approves once-monthly schizophrenia treatment
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Teva Pharmaceutical· finance.yahoo.com
2026-10-09
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical· ir.tevapharm.com
2026-10-09
Teva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation
Teva Pharmaceutical· finance.yahoo.com
2026-10-07
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
Teva Pharmaceutical· finance.yahoo.com
2026-09-16
Mayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offering - Mayer Brown
Teva Pharmaceutical· www.mayerbrown.com